TESK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5999941	1.00	5/20
SCHEMBL6001849	1.00	5/20
SCHEMBL6002058	1.00	5/20
SCHEMBL6002069	1.00	5/20
SCHEMBL6002138	1.00	5/20
SCHEMBL6001871	0.85	5/20
SCHEMBL6000061	0.84	5/20
SCHEMBL6001595	0.84	5/20
SCHEMBL1616746	0.83	5/20
SCHEMBL6001580	0.83	5/20
SCHEMBL6001860	0.83	5/20
SCHEMBL6002150	0.83	5/20
SCHEMBL6001374	0.82	5/20
SCHEMBL6001579	0.82	5/20
SCHEMBL6001363	0.82	5/20
SCHEMBL6001859	0.82	5/20
SCHEMBL1616940	0.82	5/20
SCHEMBL6001410	0.81	5/20
SCHEMBL12716196	0.81	5/20
SCHEMBL6001893	0.81	5/20

Clinical trials — most relevant to TESK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men	PHASE3	ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Cause of Familial Testicular Cancer	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Azoospermia Patients	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
COPENHAGEN Minipuberty Study	nan	UNKNOWN
Study of Sperm Molecular Factors Implicated in Male Fertility	nan	COMPLETED
Genetic Studies Spermatogenic Failure	nan	COMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or Tufting Enteropathy (TE)	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TESK1 binder may also engage these)

Protein	Name	Similarity
Q63572	—	1.000	Q63572 →
O70146	—	1.000	O70146 →
LMTK3	Serine/threonine-protein kinase LMTK3	1.000	landscape →
Q5XJV6	—	1.000	Q5XJV6 →
Q8VDG6	—	0.997	Q8VDG6 →
Q60700	—	0.996	Q60700 →
Q80XI6	—	0.995	Q80XI6 →
Q2LGB3	—	0.995	Q2LGB3 →
SIK1	Serine/threonine-protein kinase SIK1	0.995	landscape →
Q96PX9	—	0.995	Q96PX9 →
A0A8I3PMN2	—	0.994	A0A8I3PMN2 →
Q9H4M7	—	0.994	Q9H4M7 →
Q66HA1	—	0.994	Q66HA1 →
O75593	—	0.993	O75593 →
Q8BLR5	—	0.993	Q8BLR5 →
Q9H7P9	—	0.993	Q9H7P9 →
Q80UE6	—	0.993	Q80UE6 →
IRAK1	Interleukin-1 receptor-associated kinase 1	0.992	landscape →
O94761	—	0.992	O94761 →
D3ZG83	—	0.992	D3ZG83 →
Q8BZW2	—	0.992	Q8BZW2 →
Q8NDX1	—	0.992	Q8NDX1 →
Q5RA67	—	0.992	Q5RA67 →
Q96J92	—	0.991	Q96J92 →
Q8K330	—	0.991	Q8K330 →
Q9Z0E3	—	0.991	Q9Z0E3 →
O43638	—	0.991	O43638 →
Q9Y6S9	—	0.991	Q9Y6S9 →
Q18PE1	—	0.991	Q18PE1 →
Q8R2S1	—	0.991	Q8R2S1 →